Ascendis Pharma (NASDAQ:ASND) is one of the most profitable growth stocks to buy. On May 7, Ascendis Pharma reported strong financial results for Q1 2026, reaching a total revenue of €247 million. This growth was primarily driven by YORVIPATH, which generated €197 million, alongside €44 million from SKYTROFA. Additionally, the company announced an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $187.5 million, further strengthening its financial position.
The company is experiencing robust commercial momentum, highlighted by over 1,000 new US patient enrollments for YORVIPATH and more than 60 enrollments for YUVIWEL following its early April launch. Ascendis is also advancing its clinical pipeline, including positive results from the COACH combination therapy trial, while making the strategic decision to discontinue internal oncology development to better align with its long-term focus.
Operational updates for the quarter include a transition to trading ordinary shares on the Nasdaq Global Select Market and the full redemption of its 2028 convertible notes. With a net profit of €629 million and cash reserves of €573 million as of March 31, Ascendis Pharma (NASDAQ:ASND) continues to solidify its role as a leading global biopharmaceutical firm.
Ascendis Pharma (NASDAQ:ASND) develops TransCon-based therapies for unmet medical needs.
While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
Leave a comment